Breaking News

Financial Report: WuXi Pharma Tech 3Q

Lab Services up 26%, driven by China-based labs

Related CONTENT

11.13.12

WuXi Pharma Tech

3Q Revenues: $125.8 million (+21%)

3Q Earnings: $213 million (+3%)

YTD Revenues: $374.3 million (+25%)

YTD Earnings: $62.8 million (+9%)

Comments: Laboratory Services were $98.9 million in the quarter, up 26%. China-based Lab Services increased 32% to $77.0 million. U.S.-based Lab Services were up 6% to $21.9 million. Manufacturing services were $26.9 million, up 7%.

Suggested For You

Vetio Animal Health

Vetio Animal Health

Pharmatek Adds cGMP Spray Drying Capacity

Pharmatek Adds cGMP Spray Drying Capacity

Volition Opens New R&D Facility in Belgium

Volition Opens New R&D Facility in Belgium

Ametek Buys Mocon for $182m

Ametek Buys Mocon for $182m

Cytovance Biologics Names Bioprocess Development VP

Cytovance Biologics Names Bioprocess Development VP

Biological Safety Canopy Exhaust Connection Saves Energy and Improves Overall Safety Performance

Biological Safety Canopy Exhaust Connection Saves Energy and Improves Overall Safety Performance

Innovative Technologies Result in a More Sustainable and Energy-Efficient Total Exhaust Biological

Innovative Technologies Result in a More Sustainable and Energy-Efficient Total Exhaust Biological

2016 - Seventeenth Annual Salary Survey

2016 - Seventeenth Annual Salary Survey

2015 - Sixteenth Annual Salary Survey

2015 - Sixteenth Annual Salary Survey

Financial Report: WuXi PharmaTech 1Q

Financial Report: WuXi PharmaTech 1Q

Xcelience Opens UK Packaging and Distribution Hub

Xcelience Opens UK Packaging and Distribution Hub

Financial Report: WuXi PharmaTech

Financial Report: WuXi PharmaTech

Vaccine Outsourcing

Vaccine Outsourcing

Servier Selects Banook CI for Imaging Services

Servier Selects Banook CI for Imaging Services

Related Breaking News

Breaking News | cGMP Manufacture | Industry News

Valneva Inks APA with European Commission for COVID Vax

To supply up to 60 million doses of its inactivated COVID-19 vaccine candidate, VLA2001, over two years.
11.23.21
Breaking News | Industry News | R&D

AstraZeneca Unveils £1B R&D Facility in Cambridge UK

New facility, designed to the highest environmental standards, will include advanced robotics, high-throughput screening and AI-driven technology.
11.23.21
Breaking News | cGMP Manufacture | Facilities

Concept Life Sciences Receives GMP Accreditation for UK Site

Strengthens its position as a trusted partner to pharmaceutical, biotech and animal health companies.
11.23.21
Bioanalytical Services | Biologics, Proteins, Vaccines | Breaking News | Industry News | Laboratory Testing | Microbiology

Lonza Expands Microbial Development Labs

New development capacity will consolidate the microbial footprint at the Visp site and add new high throughput equipment and automation processes.
11.23.21
Breaking News | Industry News | Vials

Bormioli Pharma Joins the Glass Futures Project

Aims to research and make available state-of-the-art technologies and processes to reduce the environmental impact of glass production.
11.23.21
Breaking News | Fill/Finish | Industry News | Vials

Steriline Showcases New Robotic Nest Filling Machine

Features of the RayDyLyo closure system are designed to be more suitable to produce small and medium volumes in R&D labs or pilot lines.
11.23.21
Breaking News | Facilities

Owen Mumford Begins Construction on New Production Facility in Oxfordshire, UK

The new building is commissioned to align with the company’s sustainability agenda.
11.22.21
Breaking News | Drug Development

Regenxbio Receives FDA Orphan Drug Designation for Potential Duchenne Treatment

Marks a milestone in the development of RGX-202 and highlights the need for potential new treatment options for patients with Duchenne.
11.22.21
Breaking News | Drug Development

Neurocrine Biosciences & Sosei Group Collaborate to Develop Treatment for Neuropsychiatric Disorders

Sosei Heptares receives $100 million upfront, ongoing R&D funding and up to $2.6 billion in potential development, regulatory and commercial milestone payments.
11.22.21
Breaking News | Collaborations & Alliances | Drug Development | R&D

Evotec SE, EQRx Enter Oncology, Immunology R&D Alliance

Aims to accelerate EQRx's pipeline leveraging Evotec's data-driven, integrated R&D-platform, applied across different drug modalities and therapeutic areas.
11.19.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Trials & Filings

BioNTech's FixVac Gets Fast Track in Advanced Melanoma

FixVac platform uses a fixed combination of mRNA-encoded, tumor-associated antigens to trigger a precise immune response against cancer.
11.19.21
Breaking News | Industry News

Pfizer, BioNTech Booster Gets EUA in 18 and Older

Booster dose is to be administered at least six months after completion of the primary series.
11.19.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

Gilead Ops in For Three Programs in Arcus Biosciences Portfolio

Aims to accelerate clinical development in oncology and facilitate the exploration of treatment combinations across portfolios.
11.18.21
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News

Novo Nordisk to Acquire Dicerna Pharmaceuticals for $3.3B

Gains Dicerna’s ribonucleic acid interference (RNAi) platform to develop therapies to selectively silence genes that cause or contribute to disease.
11.18.21
Breaking News | Facilities

Arxada Invests in Industrial Biotechnological Plant in Kouřim, Czech Republic

Strengthens its capacity to support its expanding customer base.
11.18.21